Jason Chew With a 5% dividend, Bristol-Myers Squibb provides one the highest yields you can find. This makes BMY a very attractive stock for income investors, especially considering today’s near-zero.
Jason Chew After the 2000 bubble and crash, the biotech IPO has finally begun to crack open a bit. First, Ironwood tested the waters in February with the largest IPO.
In 2003, Cubist was granted approval for its novel antibiotic, Cubicin, for complicated skin and skin structure infections by Gram-positive bacteria, including drug-resistant strains. Over the next couple years, the.
Jason Chew Targacept is a company focused on CNS diseases and disorders, targeting Neuronal Nicotinic Receptors (NNRs). As a company spun off from R.J Reynolds and still located in Winston-Salem,.
Jason Chew Curis released results today for its hedghog pathway inhibitor GDC-0449 in a pivotal Phase II colorectal trial run by Roche. The company said its drug failed to extend the.
Jason Chew For years, much of Ariad’s value had been tied to its mTOR inhibitor, Ridaforolimus. Ridaforolimus is an orally bio-available analog of Rapamycin- an immunosuppresent discovered decades ago- the.
Jason Chew Genomic Health is a pure-play oncology in-vitro diagnostics company with approved products and a pipeline to drive future growth. It fits in well with the growing importance of.
After Celldex’s flubbed pre-ASCO abstract release led investor to question interim Phase II data for its cancer vaccine CDX-110 (PF-04948568), also with the generic name Rindopepimut, they made sure to.
The next several months will be an exciting time for the women’s health space, with several important events that may represent an opportunity for investors. Most notably, Pfizer (PFE) has.
Alexion got some good news today, receiving earlier than expected approval for its drug, Soliris (eculizumab), for the treatment of PNH in Japan- the world’s second largest pharmaceuticals market. Having.
(Featured in TheBigRedBiotechBlog) This Swiss pharma is the third largest pharmaceutical company both by revenue and market cap. It is one of the fastest growing companies in its peer group,.
Next Generation Antibody Technologies- Seattle Genetics Leads the Way Monoclonal Antibody Technology has revolutionized medicine. Since 1986, more than 20 Antibody drugs have been approved, with sales of $26 Billion.
Incyte Pharmaceuticals: JAK it Up Incyte Pharmaceuticals has one of the most promising pipelines in the small to mid-cap space. It has two very promising compounds in development, INCB18424 for.
The Promise Behind Celldex Celldex shares climbed steadily in the months leading up to the release of its ASCO abstracts, rising from $4.71 at the start of the year and.
The Women’s Health Initiative (WHI), a study that demonstrated several lethal side-effects of hormone replacement therapy (HRT), has left many pharmaceutical companies scrambling to advance alternative therapies to meet the.
Several weeks ago, DepoMed (NASDAQ:DEPO), a specialty pharmaceutical company, announced positive phase 3 trial results for the treatment of Post Herpetic Neuralgia (‘PHN’) with DM1796. But DepoMed’s news of success.
Vivus Pharmaceuticals shocked the health-care industry earlier this year when it announced positive phase III results for it’s new obesity miracle drug. The drug, dubbed Qnexa, is a combination of.
Pharmaceutical M&A is still robust. Rumors are spreading that Warner Chilcott (NASDAQ:WCRX) will purchase Proctor & Gamble’s (NYSE:PG) prescription drug unit as early as tomorrow. The price tag is rumored.